Company
Headquarters: Austin, TX, United States
Employees: 65
CEO: Mr. Cameron Reynolds MBA
$76.2 Million
USD as of July 1, 2025
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $222.61 B |
| Danaher | $164.98 B |
| Siemens Healthineers AG | $57.84 B |
| IDEXX Laboratories, Inc. | $53.62 B |
| Lonza Group Ltd | $47.58 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q Vet Cancer Screening Test for veterinary applications. The company also develops blood-based Nu.Q immunoassays to detect specific biomarkers. In addition, it is developing various veterinary products, including a treatment monitoring test, a disease recurrence test, and a point-of-care platform. VolitionRx Limited is based in Austin, Texas.
VolitionRx Limited has the following listings and related stock indices.
Stock: NYSE: VNRX